Baseline characteristics from CELIA: A Phase 2 study to evaluate BIIB080 in participants with Early Alzheimer’s Disease
The ongoing Phase 2 CELIA trial will assess the efficacy, safety, and tolerability of BIIB080 compared to placebo in participants with early AD.
Authors
- Amanda Edwards
- Jing Xie (ORCID: https://orcid.org/0000-0001-9676-5734)
- Szofia Bullain (ORCID: https://orcid.org/0000-0003-0142-174X)
- Ellen Huang (ORCID: https://orcid.org/0000-0003-3902-7182)
- Gioacchino Curiale (ORCID: https://orcid.org/0000-0001-8236-7698)
- Melanie Shulman
- Diana Gallagher
- Anne Unwin
- Shuang Wu
- Martin Jones
- Jessica Collins
- Guatam Baheti
- R. Matthew Hutchison
Institutions
- Biogen (United States) (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_103364
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00